Seattle Genetics Reports Fourth Quarter and Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Seattle Genetics (SGEN): In Line ADCETRIS Sales Lead to PT Reduction at Piper Jaffray
February 10, 2016 8:57 AM ESTSlowing sales of Seattle Genetics' (NASDAQ: SGEN) ADCETRIS led Piper Jaffray analyst, Edward Tenthoff, to reduce his overall value for the therapy to $1.5 billion from $1.6 billion. This leads to a lower target price for shares of Seattle Genetics of $33 (from $44). The firm maintained a Neutral rating.
ADCETRIS sales grew 27% annually to $226 million in 2015, but we forecast growth will slow to 17% to $265 million (guidance is $255-$275 million) in 2016. ADCETRIS is currently in three Phase III trials that... More
Cantor Fitzgerald Upgrades Seattle Genetics (SGEN) to Buy
February 10, 2016 7:26 AM ESTCantor Fitzgerald upgraded Seattle Genetics (NASDAQ: SGEN) from Hold to Buy with a price target of $38.00.
For an analyst ratings summary and ratings history on Seattle Genetics click here. For more ratings news on Seattle Genetics click here.
Shares of Seattle Genetics closed at $29.04 yesterday.
... MoreSeattle Genetics (SGEN) Tops Q4 EPS by 2c
February 9, 2016 4:05 PM ESTSeattle Genetics (NASDAQ: SGEN) reported Q4 EPS of ($0.18), $0.02 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $93.5 million versus the consensus estimate of $88.28 million.
In 2015, we demonstrated significant progress across our corporate priorities. For ADCETRIS, we achieved... More
